Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1998 Jun;77(12):2257–2263. doi: 10.1038/bjc.1998.375

Doxorubicin vs epirubicin, report of a second-line randomized phase II/III study in advanced breast cancer. EORTC Breast Cancer Cooperative Group.

M Bontenbal 1, M Andersson 1, J Wildiers 1, G Cocconi 1, J Jassem 1, R Paridaens 1, N Rotmensz 1, R Sylvester 1, H T Mouridsen 1, J G Klijn 1, A T van Oosterom 1
PMCID: PMC2150384  PMID: 9649142

Abstract

The EORTC Breast Cancer Cooperative Group carried out a randomized trial to compare doxorubicin with epirubicin as second-line chemotherapy in patients with metastatic breast cancer. Two hundred and fifty-nine patients with at least one site of metastatic disease entered this trial, of whom 232 patients were eligible. Treatment consisted of doxorubicin 75 mg m(-2) or epirubicin 90 mg m(-2) i.v. every 3 weeks. The overall response rates for doxorubicin and epirubicin were 36% and 28% respectively (P = 0.173). The median time to progression was 23 weeks for doxorubicin and 19 weeks for epirubicin (P = 0.063) and the median duration of response was 40 weeks for doxorubicin and 32 weeks for epirubicin (P = 0.059). The median survival was 47 weeks for doxorubicin and 44 weeks for epirubicin (P = 0.196). Leucocyte count on retreatment day (P = 0.011) and platelet nadir (P = 0.031) were significantly lower in the doxorubicin-treated group. Also mucositis (P < 0.001), diarrhoea (P = 0.005) and haemorrhage (P = 0.048) were significantly worse in the doxorubicin arm. Nine patients on doxorubicin and two patients on epirubicin experienced congestive heart failure (CHF). At the dose levels used in this study, no statistical differences in response rate and survival were found between the two treatment arms. Treatment with doxorubicin tended to result in a slightly longer duration of response and time to progression but doxorubicin was more toxic than epirubicin.

Full text

PDF
2257

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bastholt L., Dalmark M., Gjedde S. B., Pfeiffer P., Pedersen D., Sandberg E., Kjaer M., Mouridsen H. T., Rose C., Nielsen O. S. Dose-response relationship of epirubicin in the treatment of postmenopausal patients with metastatic breast cancer: a randomized study of epirubicin at four different dose levels performed by the Danish Breast Cancer Cooperative Group. J Clin Oncol. 1996 Apr;14(4):1146–1155. doi: 10.1200/JCO.1996.14.4.1146. [DOI] [PubMed] [Google Scholar]
  2. Bonfante V., Villani F., Bonadonna G. Toxic and therapeutic activity of 4'-epi-doxorubicin. Tumori. 1982 Apr 30;68(2):105–111. doi: 10.1177/030089168206800202. [DOI] [PubMed] [Google Scholar]
  3. Brambilla C., Rossi A., Bonfante V., Ferrari L., Villani F., Crippa F., Bonadonna G. Phase II study of doxorubicin versus epirubicin in advanced breast cancer. Cancer Treat Rep. 1986 Feb;70(2):261–266. [PubMed] [Google Scholar]
  4. Coates A., Gebski V., Bishop J. F., Jeal P. N., Woods R. L., Snyder R., Tattersall M. H., Byrne M., Harvey V., Gill G. Improving the quality of life during chemotherapy for advanced breast cancer. A comparison of intermittent and continuous treatment strategies. N Engl J Med. 1987 Dec 10;317(24):1490–1495. doi: 10.1056/NEJM198712103172402. [DOI] [PubMed] [Google Scholar]
  5. Ejlertsen B., Pfeiffer P., Pedersen D., Mouridsen H. T., Rose C., Overgaard M., Sandberg E., Kristensen B. Decreased efficacy of cyclophosphamide, epirubicin and 5-fluorouracil in metastatic breast cancer when reducing treatment duration from 18 to 6 months. Eur J Cancer. 1993;29A(4):527–531. doi: 10.1016/s0959-8049(05)80145-5. [DOI] [PubMed] [Google Scholar]
  6. Gasparini G., Dal Fior S., Panizzoni G. A., Favretto S., Pozza F. Weekly epirubicin versus doxorubicin as second line therapy in advanced breast cancer. A randomized clinical trial. Am J Clin Oncol. 1991 Feb;14(1):38–44. doi: 10.1097/00000421-199102000-00009. [DOI] [PubMed] [Google Scholar]
  7. Hayward J. L., Carbone P. P., Heuson J. C., Kumaoka S., Segaloff A., Rubens R. D. Assessment of response to therapy in advanced breast cancer: a project of the Programme on Clinical Oncology of the International Union Against Cancer, Geneva, Switzerland. Cancer. 1977 Mar;39(3):1289–1294. doi: 10.1002/1097-0142(197703)39:3<1289::aid-cncr2820390340>3.0.co;2-f. [DOI] [PubMed] [Google Scholar]
  8. Hoogstraten B., George S. L., Samal B., Rivkin S. E., Costanzi J. J., Bonnet J. D., Thigpen T., Braine H. Combination chemotherapy and adriamycin in patients with advanced breast cancer. A Southwest Oncology Group study. Cancer. 1976 Jul;38(1):13–20. doi: 10.1002/1097-0142(197607)38:1<13::aid-cncr2820380104>3.0.co;2-5. [DOI] [PubMed] [Google Scholar]
  9. Hortobagyi G. N., Yap H. Y., Kau S. W., Fraschini G., Ewer M. S., Chawla S. P., Benjamin R. S. A comparative study of doxorubicin and epirubicin in patients with metastatic breast cancer. Am J Clin Oncol. 1989 Feb;12(1):57–62. doi: 10.1097/00000421-198902000-00014. [DOI] [PubMed] [Google Scholar]
  10. Jain K. K., Casper E. S., Geller N. L., Hakes T. B., Kaufman R. J., Currie V., Schwartz W., Cassidy C., Petroni G. R., Young C. W. A prospective randomized comparison of epirubicin and doxorubicin in patients with advanced breast cancer. J Clin Oncol. 1985 Jun;3(6):818–826. doi: 10.1200/JCO.1985.3.6.818. [DOI] [PubMed] [Google Scholar]
  11. Launchbury A. P., Habboubi N. Epirubicin and doxorubicin: a comparison of their characteristics, therapeutic activity and toxicity. Cancer Treat Rev. 1993 Jul;19(3):197–228. doi: 10.1016/0305-7372(93)90036-q. [DOI] [PubMed] [Google Scholar]
  12. Mouridsen H. T. New cytotoxic drugs in treatment of breast cancer. Acta Oncol. 1990;29(3):343–347. doi: 10.3109/02841869009090012. [DOI] [PubMed] [Google Scholar]
  13. Perez D. J., Harvey V. J., Robinson B. A., Atkinson C. H., Dady P. J., Kirk A. R., Evans B. D., Chapman P. J. A randomized comparison of single-agent doxorubicin and epirubicin as first-line cytotoxic therapy in advanced breast cancer. J Clin Oncol. 1991 Dec;9(12):2148–2152. doi: 10.1200/JCO.1991.9.12.2148. [DOI] [PubMed] [Google Scholar]
  14. Rozencweig M., De Sloover C., Von Hoff D. D., Tagnon H. J., Muggia F. M. Anthracycline derivatives in new drug development programs. Cancer Treat Rep. 1979 May;63(5):807–808. [PubMed] [Google Scholar]
  15. Rozencweig M., ten Bokkel Huinink W., Cavalli F., Bruntsch U., Dombernowsky P., Høst H., Bramwell V., Renard G., Van Glabbeke M., Decoster G. Randomized phase II trial of carminomycin versus 4'-epidoxorubicin in advanced breast cancer. J Clin Oncol. 1984 Apr;2(4):275–281. doi: 10.1200/JCO.1984.2.4.275. [DOI] [PubMed] [Google Scholar]
  16. Schauer P. K., Wittes R. E., Gralla R. J., Casper E. S., Young C. W. A phase of I trial of 4'-epi-Adriamycin. Cancer Clin Trials. 1981 Winter;4(4):433–437. [PubMed] [Google Scholar]
  17. Taguchi T., Ogawa M., Izuo M., Terasawa T., Yoshida M., Nakajima M. [A prospective randomized trial comparing epirubicin and doxorubicin in advanced or recurrent breast cancer]. Gan To Kagaku Ryoho. 1986 Dec;13(12):3498–3507. [PubMed] [Google Scholar]
  18. Von Hoff D. D., Layard M. W., Basa P., Davis H. L., Jr, Von Hoff A. L., Rozencweig M., Muggia F. M. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med. 1979 Nov;91(5):710–717. doi: 10.7326/0003-4819-91-5-710. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES